Injurious Falls and Syncope in Older Community-Dwelling Adults Meeting Inclusion Criteria for SPRINT
The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treating adults 75 years of age or older with hypertension to reach a systolic blood pressure target of less than 120 mm Hg compared with a systolic blood pressure target of less than 140 mm Hg reduced the numbers of cardiovascular events and death without a significant increase in the number of injurious falls or syncope. 1 However, prior to the adoption of an intensive strategy to lower systolic blood pressure in the oldest segment of the population, it is prudent to determine if individuals meeting inclusion criteria for SPRINT outside the clinical trial context are similar to trial participants, especially with regard to risk for adverse outcomes. We used The Irish Longitudinal Study on Ageing 2,3 (TILDA) to compare baseline rates of injurious falls and syncope in community-dwelling older adults with the rates in the standard care group of SPRINT.
Methods | The Irish Longitudinal Study on Ageing is a nationally representative prospective cohort study of communitydwelling adults 50 years of age or older in the Republic of Ireland. 2,3 Random sampling of geographical clusters was used to select households. Data collection involved an in-home interview, a self-completed questionnaire (N = 8175), and a comprehensive health assessment (N = 5751). Mean follow-up for TILDA was 3.4 years, compared with a median of 3.4 years in SPRINT. Our study used data from wave 1 of TILDA (completed July 31, 2011) to retrospectively identify participants meeting final inclusion criteria for SPRINT. Outcomes were then reported at wave 2 (February 1, 2012-March 31, 2013) and wave 3 (March 1, 2014-December 31, 2015) follow-up. Ethical approval for TILDA was obtained from the Faculty of Health Sciences Research Ethics Committee at Trinity College Dublin. All participants provided written informed consent. We used the SPRINT eligibility criteria to identify TILDA participants who would be eligible for the trial. 1, 4 ; all SPRINT eligibility parameters apart from degree of proteinuria were available for TILDA participants. Falls and syncope were assessed either by self-report or proxy at each wave. Participants were asked if they had fallen since their last interview and, if so, if they injured themselves seriously enough to need medical treatment. These questions were repeated for syncope. All analyses were performed using R statistical software (R Foundation for Statistical Computing) and Stata, version 14.1 (StataCorp), incorporating inverse probability weighting to account for complex survey designs. P < .05 was considered significant. Figure) .
Results | The
Discussion | In a community-based prospective cohort with contemporaneous follow-up of comparable duration (TILDA), participants 75 years of age or older who met inclusion criteria for SPRINT had rates of injurious falls and syncope approximately 5-fold higher than the standard care group in SPRINT. Given the high baseline rates of falls and syncope, any increase in these rates due to intensive treatment of hypertension could result in harm. ; frailty in SPRINT determined by SPRINT-specific frailty index.
Letters

A Survey of Unregulated Direct-to-Consumer Treatment Centers Providing Stem Cells for Patients With Heart Failure
Stem cell therapy for the treatment of heart failure (HF) is under investigation but not approved by the US Food and Drug Administration (FDA).
1 Nevertheless, through direct-toconsumer promotion, "stem cell centers" claim to offer this treatment to patients. We sought to assess the type of treatments, cost, and statements made about efficacy.
Methods | Stem cell centers marketing treatment for HF were identified using a published database. 2 We used a standardized script in a telephone survey to ensure consistency in data collection. Several centers had multiple satellite locations; for these, only 1 was contacted. Inquiries included stem cell source, infusion method, treatment number, preprocedural evaluation, follow-up, and price. Representative statements by stem cell center personnel were chronicled. The board certifications of physicians named on center websites were compared against online registries.
3,4
Standard descriptive statistics were used (IBM SPSS Statistics for Windows; version 24.0). For centers that provided a range (n = 5), the mean of the minimum and maximum price was calculated. The study was deemed exempt by the Saint Louis University institutional review board. Of 61 centers listed as offering HF therapy in 2016,  2 15 were satellite sites. Seven centers no longer had active websites or had been closed by the FDA; 2 could not be contacted; 2 refused to provide data; 3 did not offer HF treatment despite online claims; 1 did not offer treatment for severe HF; and 1 required advance payment ($250) for telephone consultation.
Results |
Half of the remaining 30 centers responding to the survey were located in 3 states (8 in California, 4 in Florida, and 3 in New York). The self-reported number of procedures performed varied widely; 5 claimed more than 100. Medical records were required at only 9 centers, and a cardiologist's note was requested at 6. None of the sites discussed methodologies used to isolate or identify stem cells; most claimed to use autologous stem cells alone (24 adipose-derived, 1 from bone marrow), 2 treated with allogeneic stem cells (umbilical or placental), and 3 offered multiple sources. Stem cells were delivered intravenously in 29 centers; 1 performed direct coronary infusion. Stem cells were infused on the same day as harvest in all centers offering autologous infusions; 6 offered cell banking. Ancillary treatments (vitamin infusions and hyperbaric oxygen) were offered in 5. Follow-up was required at 2 centers.
The mean (SD) price for a single treatment was $7694 ($2737) for autologous and $6038 ($3145) for allogeneic cells. A discount ($500) was offered at 2 centers if the procedure was paid for in cash; additional procedures were offered for a discounted price (7 centers; mean discount, $3893 [$888]).
From 39 centers with websites advertising HF treatment, 79 physicians were identified: board certified in cardiology (n = 1), board certified in another field (n = 55), and unverified board certification status (n = 13). Ten had no formal medical training but were described as "naturopathic medical doctors." Characteristic statements recorded during the telephone survey are shown in the Box.
Discussion | A recent analysis identified 570 businesses in the United States engaged in direct-to-consumer marketing of stem cell interventions including centers purported to provide stem cells for cardiac repair 2 to patients with HF despite lack of FDA approval. We found that such treatment is delivered without rigorous preprocedural evaluations or postprocedural followup. Most physicians were not board certified in cardiology. The reasons why these businesses can continue to operate are not clear; in a recent publication, the former FDA commissioner did not address the FDA's role, 5 though some monitoring of these businesses does occur. Limitations. The survey was restricted to US sites only; nevertheless, the issue is global. 7 Information derived in this study cannot be independently verified; however, the data provided are largely unavailable on websites and are not publicly reported. Given the prognosis of advanced heart failure and relatively limited options, clinicians need to be aware that patients may seek out this option and thereby may expose Outcome prevalence is reported while also accounting for the attrition rate over the course of the study. Between wave 1 and wave 2 of TILDA, 46 of 407 participants (11.3%) were no longer participating in the study owing to death (n = 21), loss to follow-up (n = 2), refusal to answer questions as part of the study (n = 22), or withdrawal from the study (n = 1). Between wave 2 and wave 3, 109 of 407 participants (26.8%) were no longer participating in the study. Ascertainment of the reasons for this attrition at wave 3 is currently still ongoing at the time of writing. 
